Skip to main content

Table 2 Association between clinicopathological factors and patients with or without anastomotic leakage

From: Preoperative C-reactive protein to albumin ratio predicts anastomotic leakage after esophagectomy for thoracic esophageal cancer: a single-center retrospective cohort study

  

All case

Group NAL

Group AL

 
  

N = 295

N = 261

N = 34

p value

Age

(Years, IQR)

65 (59–71)

66 (59–71)

65 (59–71)

0.845

 

 ≥ 53

265 (89.8%)

232 (88.9%)

33 (97.1%)

0.224*

 

 < 53

30 (10.2%)

29 (11.1%)

1 (2.9%)

 

Gender

Male

241 (81.7%)

211 (80.8%)

30 (88.2%)

0.355*

 

Female

54 (18.3%)

50 (19.2%)

4 (11.8%)

 

BMI

(kg/m2, IQR)

21.2 (19.4–23.5)

21.0 (19.4–23.5)

22.2 (19.8–23.8)

0.433

 

 ≥ 22.1

114 (38.6%)

95 (36.4%)

19 (55.9%)

0.028

 

 < 22.1

181 (61.4%)

166 (63.6%)

15 (44.1%)

 

Habitual tobacco use

Yes

235 (79.7%)

204 (78.2%)

31 (91.2%)

0.11*

 

No

60 (20.3%)

57 (21.8%)

3 (8.8%)

 

Habitual alcohol use

Yes

235 (79.7%)

205 (78.5%)

30 (88.2%)

0.257*

 

No

60 (20.3%)

56 (21.5%)

4 (11.8%)

 

Steroid use

Yes

4 (1.4%)

3 (1.2%)

1 (2.9%)

0.389*

 

No

291 (98.6%)

258 (98.9%)

33 (97.1%)

 

CCI

(IQR)

0 (0–1)

0 (0–1)

0 (0–1)

0.829

 

 ≤ 2

283 (95.9%)

252 (96.6%)

31 (91.2%)

0.149

 

 ≥ 3

12 (4.1%)

9 (3.5%)

3 (8.8%)

 

Albumin

(g/dL, IQR)

3.9 (3.7–4.2)

3.9 (3.7–4.2)

3.8 (3.6–4.1)

0.203

 

 > 3.8

172 (58.3%)

157 (60.2%)

15 (44.1%)

0.075

 

 ≤ 3.8

123 (41.7%)

104 (39.8%)

19 (55.9%)

 

CRP

(mg/dL, IQR)

0.1 (0.04–0.3)

0.10 (0.04–0.28)

0.14 (0.06–0.43)

0.075

 

 ≥ 0.06

200 (67.8%)

171 (65.5%)

29 (85.3%)

0.02

 

 < 0.06

95 (32.2%)

90 (34.5%)

5 (14.7%)

 

PNI

(IQR)

47.4 (44.4–50.7)

47.4 (44.4–50.7)

48.0 (44.3–50.6)

0.82

 

 ≥ 42.5

258 (87.5%)

226 (86.6%)

32 (94.1%)

0.279*

 

 < 42.5

37 (12.5%)

35 (13.4%)

2 (5.9%)

 

CAR

(IQR)

0.024 (0.01–0.08)

0.024 (0.009–0.073)

0.037 (0.015–0.123)

0.072

 

 ≥ 0.0139

200 (67.8%)

170 (65.1%)

30 (88.2%)

0.007

 

 < 0.0139

95 (32.2%)

91 (34.9%)

4 (11.8%)

 

mGPS

0

235 (79.7%)

210 (80.5%)

25 (73.5%)

0.345

 

1, 2

60 (20.3%)

51 (19.5%)

9 (26.5%)

 

ASA-PS

1, 2

275 (93.2%)

245 (93.9%)

30 (88.2%)

0.265*

 

3

20 (6.8%)

16 (6.1%)

4 (11.8%)

 

Location of tumor

Ut

53 (18.0%)

47 (18.0%)

6 (17.6%)

0.887

 

Mt

172 (58.3%)

151 (57.9%)

21 (61.8%)

 
 

Lt

70 (23.7%)

63 (24.1%)

7 (20.6%)

 

cT (UICC8)

1, 2

161 (54.6%)

140 (53.6%)

21 (61.8%)

0.371

 

3, 4

134 (45.4%)

121 (46.4%)

13 (38.4%)

 

cN (UICC8)

Yes

162 (54.9%)

144 (55.2%)

18 (52.9%)

0.806

 

No

133 (45.1%)

117 (44.8%)

16 (47.1%)

 

cStage (UICC8)

I, II

157 (53.2%)

138 (52.9%)

19 (55.9%)

0.741

 

III, IV

138 (46.8%)

123 (47.1%)

15 (44.1%)

 

Preoperative treatment

Chemotherapy

154 (52.2%)

132 (50.6%)

22 (64.7%)

0.158

 

Chemoradiotherapy

16 (5.4%)

16 (6.1%)

0 (0.0%)

 
 

Surgical only

125 (43.4%)

113 (43.3%)

12 (35.3%)

 
  1. *Fisher's exact test
  2. IQR interquartile range, BMI body mass index, CCI Charlson comorbidity index, CRP serum C-reactive protein;
  3. PNI Onodera’s prognostic nutritional index, CAR C-reactive protein to albumin ratio, mGPS modified Glasgow prognostic score
  4. ASA-PS the American Society of Anesthesiologists classification of physical status
  5. UICC the Union for International Cancer Control